Clinical and preclinical activity of 2′,2′- difluorodeoxycytidine (gemcitabine)

This publication has 8 references indexed in Scilit:

• Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts
  Annals of Oncology, 1993
• Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.
  Journal of Clinical Oncology, 1992
• Phase II study of gemcitabine in non small cell lung cancer (NSCLC): B. Lund, H. Anderson, J. Walling, N. Thatcher, H.H.Hansen Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark, and Wythenshawe Hospital, Manchester, England
  Lung Cancer, 1991
• A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
  Journal of Clinical Oncology, 1991
• Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells
  Anti-Cancer Drugs, 1991
• Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
  Cancer Chemotherapy and Pharmacology, 1991
• 2',2'-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia Cells
  Nucleosides, Nucleotides and Nucleic Acids, 1989
• Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2'-difluoro-D-ribofuranosyl nucleosides
  The Journal of Organic Chemistry, 1988